Ero Copper Corp (ERO)vsVertex Pharmaceuticals Inc (VRTX)
ERO
Ero Copper Corp
$25.41
+2.87%
BASIC MATERIALS · Cap: $2.65B
VRTX
Vertex Pharmaceuticals Inc
$454.97
+1.42%
HEALTHCARE · Cap: $113.95B
Smart Verdict
WallStSmart Research — data-driven comparison
Vertex Pharmaceuticals Inc generates 1427% more annual revenue ($12.00B vs $785.84M). ERO leads profitability with a 33.6% profit margin vs 32.9%. ERO trades at a lower P/E of 10.0x. ERO earns a higher WallStSmart Score of 68/100 (B-).
ERO
Strong Buy68
out of 100
Grade: B-
VRTX
Strong Buy66
out of 100
Grade: B-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-83.1%
Fair Value
$17.20
Current Price
$25.41
$8.21 premium
Margin of Safety
+36.5%
Fair Value
$716.04
Current Price
$454.97
$261.07 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Attractively priced relative to earnings
Every $100 of equity generates 35 in profit
Keeps 34 of every $100 in revenue as profit
Strong operational efficiency at 43.6%
Revenue surging 161.3% year-over-year
Reasonable price relative to book value
Keeps 33 of every $100 in revenue as profit
Strong operational efficiency at 39.6%
Safe zone — low bankruptcy risk
Large-cap with strong market position
Every $100 of equity generates 23 in profit
Conservative balance sheet, low leverage
Areas to Watch
Earnings declined 11.0%
Expensive relative to growth rate
Moderate valuation
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : ERO
The strongest argument for ERO centers on P/E Ratio, Return on Equity, Profit Margin. Profitability is solid with margins at 33.6% and operating margin at 43.6%. Revenue growth of 161.3% demonstrates continued momentum.
Bull Case : VRTX
The strongest argument for VRTX centers on Profit Margin, Operating Margin, Altman Z-Score. Profitability is solid with margins at 32.9% and operating margin at 39.6%.
Bear Case : ERO
The primary concerns for ERO are EPS Growth.
Bear Case : VRTX
The primary concerns for VRTX are PEG Ratio, P/E Ratio, Piotroski F-Score.
Key Dynamics to Monitor
ERO profiles as a growth stock while VRTX is a mature play — different risk/reward profiles.
ERO carries more volatility with a beta of 1.51 — expect wider price swings.
ERO is growing revenue faster at 161.3% — sustainability is the question.
VRTX generates stronger free cash flow (349M), providing more financial flexibility.
Bottom Line
ERO scores higher overall (68/100 vs 66/100), backed by strong 33.6% margins and 161.3% revenue growth. VRTX offers better value entry with a 36.5% margin of safety. Both earn "Strong Buy" and "Strong Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Ero Copper Corp
BASIC MATERIALS · COPPER · USA
Ero Copper Corp. The company is headquartered in Vancouver, Canada.
Vertex Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Vertex Pharmaceuticals, Inc. is an American biopharmaceutical company based in Boston, Massachusetts.
Compare with Other COPPER Stocks
Want to dig deeper into these stocks?